© 2025 CSRXP- All Rights Reserved

ICYMI: INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW ANNOUNCES ANNUAL LAUNCH PRICE AND ACCESS REPORT FOR 2025
Jan 22, 2025
New Analysis Will Help Shine a Light on Big Pharma’s Increasingly Out-of-Control Prices for New Brand Name Prescription Drugs
Today, the Institute for Clinical and Economic Review (ICER) announced plans to release a new analysis annually, titled the “Launch Price and Access Report,” to examine launch pricing for U.S. Food and Drug Administration (FDA)-approved treatments, their affordability, access to these treatments and the value they bring to the overall health system.
The analysis will examine all novel drug approvals in the previous two years, including:
- Analyzing list and net price trends
- Conducting an in-depth review of drugs that were subject to an ICER analysis
- Analyzing affordability and access concerns, such as trends in patient out-of-pocket costs
“There is no better time to provide an independent analysis on trends in launch pricing – both list and net – and patient access. ICER typically evaluates promising treatments that pose potential affordability challenges for the U.S. health system. Through this work, ICER will continue to work towards a health system where the pricing of innovative treatments are tied to value, while still ensuring affordability and access for patients,” said ICER’s Vice President of Research Foluso Agboola, MBBS, MPH, in a statement.
The report is tentatively expected to be released in the fourth quarter later this year.
Big Pharma has been setting increasingly out-of-control launch prices on brand name drugs coming to market for the first time — to maximize profits on products right at the start of their exclusivity periods, and set a higher starting point from which to further hike prices.
Last February, Reuters released an analysis which found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000. This number was 35 percent higher than the previous year.
The previous March, The Wall Street Journal released a report which found that the median monthly price for a newly approved drug nearly tripled from 2011 to 2022.
Read more on a December 2024 ICER analysis which found Big Pharma hiking prices that outpace the rate of inflation on brand name drugs with no added clinical benefit for patients HERE.
Read more on Big Pharma’s first round of price increases for 2025 HERE.
Read more on bipartisan, market-based solutions to hold Big Pharma accountable HERE.
###